Anthera Pharmaceuticals (ANTH) : Analyst Rating Update

Anthera Pharmaceuticals (ANTH) : Zacks Investment Research ranks Anthera Pharmaceuticals (ANTH) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 3 research analysts is 1, which indicates as a Strong Buy.

Anthera Pharmaceuticals (ANTH) : Currently there are 3 street experts covering Anthera Pharmaceuticals (ANTH) stock. The most bullish and bearish price target for the stock is $14 and $9 respectively for the short term. The average price target of all the analysts comes to $11. The estimated standard deviation from the target is $2.65.

Anthera Pharmaceuticals (NASDAQ:ANTH): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.23 and $3.23 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.31, notching a gain of 2.16% for the day. The total traded volume was 669,263 . The stock had closed at $3.24 on the previous day.

The company shares have dropped -61.15% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $11.65 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $3.37 and the 200 Day Moving Average price is recorded at $3.53.

Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.